Zacks Research Has Negative Estimate for BMY Q3 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Stock analysts at Zacks Research reduced their Q3 2025 EPS estimates for shares of Bristol Myers Squibb in a research note issued to investors on Thursday, August 14th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $1.62 per share for the quarter, down from their previous forecast of $1.70. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q4 2025 earnings at $1.63 EPS, Q1 2026 earnings at $1.45 EPS, Q2 2026 earnings at $1.62 EPS, FY2026 earnings at $5.88 EPS and Q2 2027 earnings at $1.55 EPS.

Several other research analysts have also recently weighed in on the stock. Jefferies Financial Group lowered their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Argus raised shares of Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Finally, Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $56.38.

Bristol Myers Squibb Trading Up 1.3%

Shares of BMY stock opened at $48.45 on Monday. The company’s 50-day moving average price is $47.23 and its 200-day moving average price is $51.39. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The stock has a market cap of $98.62 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 2.48 and a beta of 0.36. Bristol Myers Squibb has a twelve month low of $42.96 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same period last year, the company earned $2.07 EPS.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.1%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 100.00%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds have recently added to or reduced their stakes in the stock. Marcum Wealth LLC increased its stake in Bristol Myers Squibb by 1.0% in the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company’s stock valued at $1,177,000 after purchasing an additional 193 shares during the last quarter. Beacon Investment Advisory Services Inc. increased its stake in Bristol Myers Squibb by 2.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 212 shares during the last quarter. Exchange Capital Management Inc. increased its stake in Bristol Myers Squibb by 0.4% in the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock valued at $2,541,000 after purchasing an additional 220 shares during the last quarter. 1858 Wealth Management LLC increased its stake in Bristol Myers Squibb by 3.6% in the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 221 shares during the last quarter. Finally, Parsons Capital Management Inc. RI increased its stake in Bristol Myers Squibb by 0.3% in the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock valued at $3,615,000 after purchasing an additional 224 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.